Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Matt Gatlin

Nurse Practitioner Gulfport, MS Nurse Practitioner

NPI 1629634506 CMS profile 11222234

1340 Broad Ave Ste 300, Gulfport, MS 39501

Open in the dashboard

General payments

$4,103

170 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matt Gatlin of Gulfport, MS is reported in the CMS Open Payments database as having received $4,103 across 170 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $251 12
2024 General $321 14
2023 General $678 29
2022 General $981 50
2021 General $1,872 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matt Gatlin
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Matt Gatlin were reported at $251. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Matt Gatlin Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,872 $135 $40–$426 $132
2022 $981 $152 $48–$470 $149
2023 $678 $166 $54–$529 $160
2024 $321 $173 $55–$556 $164
2025 $251 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. La Jolla Pharmaceutical Company $885 11 payments
  2. Astellas Pharma US Inc $836 27 payments
  3. Gilead Sciences, Inc. $522 27 payments
  4. ViiV Healthcare Company $395 22 payments
  5. Melinta Therapeutics, Inc. $386 22 payments
  6. Paratek Pharmaceuticals, Inc. $364 20 payments
  7. Merck Sharp & Dohme Corporation $212 11 payments
  8. AbbVie, Inc. $182 11 payments
  9. Theratechnologies Inc. $58 3 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $57 3 payments
  11. Other $205 13 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,769 165 payments
  2. Education $334 5 payments
Products named General payments · program years 2021–2025
  1. XERAVA $885 11 payments
  2. NUZYRA $364 20 payments
  3. Kimyrsa $329 19 payments
  4. Cresemba Infectious Diseases $231 9 payments
  5. Rezzayo $224 12 payments
  6. CABENUVA $210 11 payments
  7. DIFICID $189 10 payments
  8. DOVATO $185 11 payments
  9. Vabomere $145 9 payments
  10. CRESEMBA Hospital And Transplant $114 7 payments
  11. Other $1,412 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$62,484

Medicare's payments for the services billed

Medicare patients

370

Average age 74

Services billed

1,082

186 women, 184 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 58%
Arthritis 57%
Diabetes 55%
Ischemic heart disease 52%
Chronic kidney disease 51%
Atrial fibrillation 49%
COPD 44%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Cresemba
  • Astellas Pharma US Inc $160
$160 — —
Rezzayo
  • Melinta Therapeutics, Inc. $60
$60 — —
Kimyrsa
  • Melinta Therapeutics, Inc. $60
$60 — —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $21
$21 — —
ZERBAXA
  • Merck Sharp & Dohme Corporation $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

170 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record